Clinical-stage precision medicine company EXACT Therapeutics AS (Euronext Growth Oslo:EXTX) on Tuesday announced positive final results from its Phase 1 ACTIVATE trial, evaluating Acoustic Cluster Therapy (ACT) in combination with chemotherapy in patients with liver metastases from colorectal cancer.
The data demonstrated that ACT-treated tumours had significantly greater diameter reduction compared to control tumours among chemotherapy responders (-29% vs. -7%, p
MSD expands clinical development of Orion's opevesostat to include women's cancers
Promontory Therapeutics reports successful FDA meeting after Phase 2 study of PT-112
Trevi Therapeutics reports additional results from Phase 2a RIVER trial of Haduvio
Accropeutics reports positive data from Phase 2 psoriasis treatment trial
NextCell Pharma partners with Fujifilm Irvine Scientific to deliver integrated MSC solutions
Lifecare files for first human trial of glucose monitoring implant, targeting CE-mark
EXACT Therapeutics reports strong Phase 1 results for ACTIVATE trial in colorectal liver metastases
Shanton to present data from gout study at EULAR 2025 Congress
UCB and Domino Data Lab partner to modernise Statistical Computing Environment for life sciences
WuXi XDC awarded honours in 2025 Extel ranking
Ionis reports positive Phase 3 results for olezarsen in moderate hypertriglyceridemia
Zai Lab secures FDA Fast Track designation for ZL-1310 to treat small cell lung cancer
Japan approves GSK's Blenrep combinations for relapsed or refractory multiple myeloma
Oneness and Microbio (Shanghai) partnership drug selected for ATS 2025 oral presentation